Preclinical Data from Kymera Therapeutics’ Collaborations Demonstrate Therapeutic Potential of STAT3 and IRAKIMiD Degraders at the ASH Annual Meeting
Current TAP Partner
WATERTOWN, Mass., Dec. 12, 2022 - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that preclinical data from collaborations for its STAT3 and IRAKIMiD degraders was presented at the American Society of Hematology (ASH) Annual Meeting, taking place from December 10 - 13, 2022 in New Orleans, Louisiana.
Presentations at ASH Annual Meeting:
- Title: Leveraging Pre-Clinical Animal Model of CTCL to Explore Therapeutic Potential of a Novel STAT3 Degrader
- Abstract Number: 1545
- Session Time: 5:30 PM – 7:30 PM CT, December 10, 2022
- Location: Ernest N. Morial Convention Center, Hall D
- Presenter: Sergei Koralov, PhD, Department of Pathology, New York University School of Medicine
- Title: Precision Targeting of MYD88 Mutant DLBCL Using the Novel Combination of Irakimids and BCL2 Inhibition
- Abstract Number: 3995
- Session Time: 6:00 PM – 8:00 PM CT, December 12, 2022
- Location: Ernest N. Morial Convention Center, Hall D
- Presenter: Andre Grilo, PhD, Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center